What is the rationale for using genome editing to target JAK2 V617F in myeloproliferative neoplasms?
JAK2 inhibitors eliminate mutant cells in all patients
JAK2 inhibitors provide clinical benefit but fail to eliminate mutant cells, and patients with VAF reduction have better long-term outcomes
Genome editing is cheaper than current JAK2 inhibitors